ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Price, Quote, News and Overview
NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
ARCT Quote, Performance and Key Statistics
11.98
-0.23 (-1.88%)
The current stock price of ARCT is 11.98 USD. In the past month the price decreased by -17.27%. In the past year, price decreased by -33.74%.
ARCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.78 | 351.27B | ||
| AMGN | AMGEN INC | 13.05 | 153.09B | ||
| GILD | GILEAD SCIENCES INC | 14.25 | 137.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.17 | 96.46B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 60.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 56.73B | ||
| ARGX | ARGENX SE - ADR | 72.53 | 41.15B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.66 | 32.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.77B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.85B | ||
| INSM | INSMED INC | N/A | 20.74B | ||
| NTRA | NATERA INC | N/A | 19.26B |
Related stock screener links
About ARCT
Company Profile
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Company Info
ARCTURUS THERAPEUTICS HOLDIN
10628 Science Center Dr Ste 250
San Diego CALIFORNIA 92121 US
CEO: Joseph E. Payne
Employees: 174
Phone: 18589002660
ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ
What is the stock price of ARCTURUS THERAPEUTICS HOLDIN today?
The current stock price of ARCT is 11.98 USD. The price decreased by -1.88% in the last trading session.
What is the ticker symbol for ARCTURUS THERAPEUTICS HOLDIN stock?
The exchange symbol of ARCTURUS THERAPEUTICS HOLDIN is ARCT and it is listed on the Nasdaq exchange.
On which exchange is ARCT stock listed?
ARCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARCTURUS THERAPEUTICS HOLDIN stock?
18 analysts have analysed ARCT and the average price target is 60.55 USD. This implies a price increase of 405.43% is expected in the next year compared to the current price of 11.98. Check the ARCTURUS THERAPEUTICS HOLDIN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARCTURUS THERAPEUTICS HOLDIN worth?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a market capitalization of 324.90M USD. This makes ARCT a Small Cap stock.
How many employees does ARCTURUS THERAPEUTICS HOLDIN have?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) currently has 174 employees.
What are the support and resistance levels for ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a support level at 11.97 and a resistance level at 12.78. Check the full technical report for a detailed analysis of ARCT support and resistance levels.
Is ARCTURUS THERAPEUTICS HOLDIN (ARCT) expected to grow?
The Revenue of ARCTURUS THERAPEUTICS HOLDIN (ARCT) is expected to decline by -47.59% in the next year. Check the estimates tab for more information on the ARCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARCT, evaluating the profitability, health, valuation and growth aspects
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Sales and EPS estimates to see what analysts future expectations are.
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Chart to make your own analysis
- ARCTURUS THERAPEUTICS HOLDIN (ARCT) Latest news and press-releases to stay up to date.
Does ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock pay dividends?
ARCT does not pay a dividend.
When does ARCTURUS THERAPEUTICS HOLDIN (ARCT) report earnings?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT)?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.53).
What is the Short Interest ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
The outstanding short interest for ARCTURUS THERAPEUTICS HOLDIN (ARCT) is 17.94% of its float. Check the ownership tab for more information on the ARCT short interest.
ARCT Technical Analysis
ARCT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARCT. While ARCT seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARCT Financial Highlights
Over the last trailing twelve months ARCT reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS increased by 35.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.56% | ||
| ROE | -29.18% | ||
| Debt/Equity | 0.06 |
ARCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ARCT. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -8.85% and a revenue growth -47.59% for ARCT